- Conditions
- Early Course Schizophrenia Spectrum Disorder
- Interventions
- CVL-562 (PF-06412562) 1 mg, CVL-562 (PF-06412562) 4 mg, CVL-562 (PF-06412562) 15 mg, CVL-562 (PF-06412562) 25 mg, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • New York, New York • Stony Brook, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- PF-06412562 3mg BID, PF-06412562 9mg BID, PF-06412562 45mg BID, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Arcadia, California • Glendale, California • Baltimore, Maryland + 2 more
- Conditions
- Healthy
- Interventions
- 3 mg PF-06412562, 10 mg PF-06412562, 25 mg PF-06412562, PF-06412562 TBD mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy
- Interventions
- PF-06412562
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Parkinson Disease
- Interventions
- PF-06412562, Standard of Care Placebo
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Parkinson's Disease
- Interventions
- PF-06412562, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 5
- States / cities
- Aventura, Florida • Baco Raton, Florida • South Miami, Florida + 2 more
- Conditions
- Healthy
- Interventions
- PF-06412562 3mg BID, PF-06412562 15mg BID, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Arcadia, California • Glendale, California
- Conditions
- Healthy Male Volunteers
- Interventions
- PF-06412562
- Drug
- Lead sponsor
- Invicro
- Other
- Eligibility
- 20 Years to 55 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut